Market Overview

Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

Share:

Glancy
Prongay & Murray LLP
("GPM") announces that it has filed a class
action lawsuit in the United States District Court for the Southern
District of California on behalf of persons and entities that acquired
ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD)
securities between April 29, 2016 and July 9, 2018, inclusive
(the "Class Period"), asserting claims under Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.

Investors are hereby notified that they have 60 days from the
date of this notice
to move the Court to serve as lead plaintiff in
this action.

Investors suffering losses on their ACADIA investments are encouraged to
contact Lesley Portnoy of GPM to discuss their legal rights at
310-201-9150 or by email to shareholders@glancylaw.com,
or visit the ACADIA case page on our website at www.glancylaw.com/case/acadia-pharmaceuticals-inc.

On April 9, 2018, CNN reported that "[p]hysicians, medical researchers
and other experts told CNN that they worried that [NUPLAZID] had been
approved too quickly, based on too little evidence that it was safe or
effective. And given these mounting reports of deaths, they say that
more needs to be done to assess Nuplazid's true risks." On this news,
ACADIA's share price fell $5.03 per share, or 23.4%, to close at $16.50
per share on April 9, 2018, thereby injuring investors.

The complaint filed in this class action alleges that, throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company's business, operations, and prospects. Specifically,
Defendants failed to disclose: (1) that adverse events and safety
concerns related to NUPLAZID threatened the drug's initial and
continuing FDA approval; (2) that ACADIA engaged in business practices
likely to attract regulatory scrutiny; and (3) that, as a result of the
foregoing, Defendants' statements about ACADIA's business, operations,
and prospects, were materially false and/or misleading and/or lacked a
reasonable basis.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased ACADIA securities during the Class Period, you may move
the Court no later than 60 days from the date of this notice to
ask the Court to appoint you as lead plaintiff. To be a member of the
Class you need not take any action at this time; you may retain counsel
of your choice or take no action and remain an absent member of the
Class. If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, of
GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at
310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!